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Introduction: In 2003, consolidation docetaxel was a promising
concept for unresectable stage IIIA/B nonsmall cell lung cancer
(NSCLC). To test the hypothesis that chemoradiotherapy with
carboplatin and irinotecan followed by consolidation docetaxel
would be feasible and clinically active, we conducted a phase II
study.
Methods: Thirty-two patients with unresectable stage IIIA/B
NSCLC received irinotecan (30 mg/m2) and carboplatin dosed to a
target area under the concentration curve of 2, each administered
weekly for 7 weeks. Concurrent radiotherapy was administered
more than 7 weeks to a total dose of 63 Gy in 35 fractions.
Consolidation docetaxel (75 mg/m2) was administered every 3
weeks for 3 doses 4 weeks after chemoradiotherapy. The primary
end point was objective response rate by RECIST.
Results: Complete responses occurred in 4 patients and partial
responses occurred in 14, for an objective response rate of 56.3%
(95% confidence interval [CI], 37.7–73.6%). Median progression-
free survival was 6.5 months (95% CI, 4.6–13.5); median duration
of survival was 14.8 months (95% CI, 6.9–27.3). The most common
hematologic toxicity was leukopenia, which were grade 3 or 4 in 16
patients (50%). Radiation pneumonitis (grade 2) occurred in 13 of
31 treated patients (42%).
Conclusions: These findings suggested that concurrent chemoradio-
therapy with carboplatin and irinotecan followed by consolidation
docetaxel is clinically active based on median survival in patients
with unresectable stage III NSCLC; however, the 42% incidence of
clinical radiation pneumonitis was unexpected and warrants further
investigation to determine the mechanism and preventive strategies.
(J Thorac Oncol. 2010;5: 533–539)
Therapeutic advances have led to improved survival inpatients with unresectable stage III nonsmall cell lung
cancer (NSCLC), but the optimal treatment remains in flux.
Current recommendations include platinum-based doublets
with concurrent radiotherapy to the involved lung field.1–3
Platinum agents have the advantage of being suitable for
delivery at full doses during concurrent radiotherapy. Che-
moradiotherapy with cisplatin and etoposide is an established
approach and led to a median survival of 15 months in a
phase II study conducted by the Southwest Oncology Group
(SWOG 9019).4 To improve this outcome, SWOG added
docetaxel as consolidation after the same concurrent chemo-
radiotherapy schema from SWOG 9019, which yielded an
impressive median survival of 26 months in a phase II study
(SWOG 9504).5 This median survival result was validated
again in a phase III study (SWOG 0023)6 in which patients
received the SWOG 9504 schema followed by randomization
to receive placebo or maintenance gefitinib; median survival
was 35 months. Although consolidation with docetaxel did
not improve survival in another phase III study (HOG LUN
01-24/USO-023), the median survival remained in the same
range (23 months).7
Thus far, no single platinum-based doublet regimen has
emerged as being superior in randomized studies.1–3 Carbo-
platin is attractive because it is less toxic than cisplatin, when
either is combined with etoposide.8 Newer agents are being
evaluated in combination with platinum analogues for their
ability to improve survival beyond that achieved with estab-
lished regimens. Irinotecan is an attractive alternative be-
cause of its properties as a radiosensitizer9; widespread use
for lung cancer, especially in Asia; and favorable safety
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profile compared with other agents. Weekly irinotecan with
concurrent radiotherapy was feasible in phase I studies, first
as monotherapy10,11 and, subsequently, in combination with
carboplatin.12–14 The dose-limiting toxicities of chemoradio-
therapy with weekly irinotecan and carboplatin were nausea,
vomiting, and esophagitis.12 These early studies provided
preliminary evidence of clinical activity, with objective re-
sponse rates of 60 to 72%.12–14
Based on the evidence available in 2003, when consol-
idation chemotherapy was a promising concept because of the
results of the SWOG 9504 study,5 we hypothesized that
chemoradiotherapy with weekly carboplatin and irinotecan
followed by consolidation docetaxel would be feasible and
clinically active. To test this hypothesis, we conducted an
open-label, investigator-initiated, single-arm phase II study of
patients with unresectable stage III NSCLC. The primary
objective was to determine the response rate; secondary
objectives were to determine the safety of this new combi-
nation regimen and to estimate progression-free and overall
survival.
MATERIALS AND METHODS
Eligibility
Adults (18 years) were eligible if they had histolog-
ically or cytologically confirmed NSCLC that had not been
treated with systemic chemotherapy, thoracic radiotherapy, or
surgical resection. Patients had to have clinical evidence of
unresectable stage IIIA or IIIB disease confirmed by radio-
logic studies, which include computed tomography (CT)
scans. Positron emission tomography scans were not required
but were allowed to be used per investigator discretion;
patients with malignant pleural or pericardial effusion were
excluded. Patients also had to have measurable disease,
Eastern Cooperative Oncology Group performance status of 0
or 1, adequate blood cell counts (absolute neutrophil count
1500/l, platelet count 100,000/l, and hemoglobin
8.0 g/dl), total bilirubin less than the institution’s upper
normal limit, and creatinine less than twice the institution’s
upper normal limit. Baseline pulmonary function test was not
a required test to entry the study, but it was extremely
encouraged to be performed. Exclusion criteria were major
surgery within 3 weeks, New York Heart Association class 3
or 4 heart disease, myocardial infarction within 6 months,
congestive heart failure, unstable angina, clinically significant
pericardial effusion or arrhythmia, peripheral neuropathy
grade more than 1, another malignancy within 5 years, and
hypersensitivity to study drug components. Women could not
be pregnant or lactating; patients of childbearing potential
had to use contraception. All patients provided written in-
formed consent. The University of Miami Institutional Re-
view Board approved the study, which was conducted in
accordance with federal and institutional regulations.
Therapy
Chemotherapy was administered intravenously on an
outpatient basis unless hospitalization was required for an-
other reason. Irinotecan (30 mg/m2) and carboplatin dosed to
a target area under the concentration curve of 2 were admin-
istered weekly for 7 weeks on days 1, 8, 15, 22, 29, 36, and
43 with radiotherapy. The carboplatin dose was calculated
using the Calvert formula (total dose in mg  target area
under the concentration curve  [creatinine clearance in
ml/min  25]). Thirty minutes before chemotherapy, pre-
medication consisted of a 5-hydroxytryptamine3 receptor an-
tagonist, dexamethasone (10 mg), and atropine (0.25 mg).
Epoetin alfa was started at standard doses when hemoglobin
was less than or equal to 10 g/dl or hematocrit was less than
or equal to 33%. Prophylactic granulocyte colony-stimulating
factor was administered with subsequent cycles if a patient
had afebrile grade 4 neutropenia for more than or equal to 5
days or neutropenic fever based on existing guidelines.15
Radiotherapy with 1.8 Gy/d was started within 24 hours
of the first day of chemotherapy and was delivered Monday
through Friday for 5 weeks. After 45 Gy, radiotherapy to the
primary tumor and nodal metastases was boosted to 2 Gy/d
(18 Gy in 9 fractions) for a total dose of 63 Gy in 35 fractions
over 7 weeks. Three-dimensional treatment planning methods
were used to delineate the treatment targets and normal
structures, and heterogeneity corrections were used in dose
calculation. Anteroposterior-posteroanterior fields were used
initially to treat the primary lung and nodal tumor, and the
elective mediastinal and ipsilateral hilar nodes to a dose of 45
Gy, followed by oblique off-cord beams to a dose of 18 Gy
to minimize the spinal cord and the lung dose for the boost
field treatment were used. Intensity-modulated radiation ther-
apy was not allowed in this trial. Targets were defined in
accordance with a report by the International Commission on
Radiation Units and Measurements16 as follows: gross tumor
volume encompassed all detectable tumors and lymph nodes
with a short-axis diameter more than 1 cm observed on CT
scans. Clinical target volume included gross tumor volume
and noninvolved mediastinal and ipsilateral hilar nodes.
Treatment planning target volume included clinical target
volume plus a 10- to 15-mm margin. Contouring of target
volumes and normal tissues (esophagus, spinal cord, and
lung) was performed on each section. The lungs were treated
as a single organ for radiation treatment planning and dose
calculation.
In the absence of progressive disease, defined by RE-
CIST criteria with CT or positron emission tomography scan,
3 to 4 weeks after completing chemoradiotherapy and after
resolution of toxicity, consolidation docetaxel (75 mg/m2)
was administered every 3 weeks on days 1, 21, and 42.
Premedications consisted of 8 mg of dexamethasone orally
for 6 doses and, at the discretion of the treating physician,
5-hydroxytryptamine3 receptor antagonist. Twenty-four
hours after completing docetaxel, pegfilgrastim (6 mg) was
administered subcutaneously. Dose delays and reductions
were specified for grade 3 or 4 toxicities during chemoradio-
therapy and consolidation therapy and were generally consis-
tent with existing guidelines.17–19
Follow-Up
Follow-up evaluation included physical examination
with assessment of performance status, tumor staging,
complete blood cell counts, and laboratory studies. Screen-
ing studies with assessment of toxicity (and without tumor
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staging) were repeated weekly during chemoradiotherapy,
3 to 4 weeks after completing chemoradiotherapy, and 4 to
6 weeks after consolidation therapy. Toxicities were
graded according to the National Cancer Institute Common
Toxicity Criteria version 3.0.20 Response was determined 3
to 4 weeks after completing chemoradiotherapy and 4 to 6
weeks after consolidation therapy by RECIST with CT
scans.21 Complete and partial response had to be confirmed
in two assessments performed at least 4 weeks apart.
Subsequent follow-up was every 3 months at the discretion
of the treating physician.
Statistical Methods
Target sample size was a total of 32 patients based on
the institution’s 18-month enrollment capacity and was ex-
pected to yield 30 evaluable patients who completed at least
1 treatment cycle. Sample size was based on precision of a
two-sided 95% confidence interval (CI) estimate of the over-
all response rate. More specifically, with 32 patients and a
study response rate approximating the target response rate of
60%, the lower confidence bound using the exact method
would rule out a null rate of 40%. Progression-free and
overall survival were estimated by the Kaplan-Meier method,
with corresponding two-sided 95% CIs for median times and
survival proportions based on Greenwood’s variance and the
log-transformation method, respectively.22 For progression-
free survival, follow-up was measured from study enrollment
to documented evidence of disease progression or death,
whichever occurred first, or last documented progression-free
status (censored observations). Overall survival was mea-
sured from study enrollment to date of death or last contact
(censored observations).
RESULTS
Thirty-two patients were enrolled between January
2004 and April 2007. Baseline patient characteristics and
demographics are listed in Table 1. The median duration of
treatment was 16 weeks (range, 1–26 weeks). Only 17 pa-
tients (53%) completed chemoradiotherapy and were able to
proceed to consolidation with docetaxel (median duration, 18
weeks; range, 8–26 weeks). Reasons for not receiving con-
solidation chemotherapy were disease progression during
chemoradiotherapy (n  7), radiation pneumonitis (n  2),
pneumonia (n  2), neutropenic fever (n  1), myocardial
infarction resulting in removal from the study (n  1),
withdrawal of patient consent (n  1), and poor performance
status (n  1).
Response and Survival
The best overall response during the study was 4
complete and 14 partial responses for an objective response
rate of 56.3% (95% CI, 37.7–73.6%; Table 2).
The estimated median progression-free survival was
6.5 months (95% CI, 4.6 –13.5; Figure 1). Six patients
remained progression free after a median follow-up of 33.5
months (range, 2.0 –45.5 months), including 1 patient who
had stable disease at time of last follow-up at 2 months and
subsequently died because of toxicity at 7.1 months.
Twenty-six patients had disease progression or disease-
related death after a median follow-up of 5.3 months
(range, 0.3–19.5 months), including 1 patient who died
because of disease progression at 4.2 months and 1 without
disease progression who died because of toxicity at 5.3
months. Kaplan-Meier estimates of progression-free sur-
vival were 36% (95% CI, 20–52%) at 1 year and 16%
(95% CI, 6–31%) at 2 years.
The estimated median duration of survival in all
patients was 14.8 months (95% CI, 6.9 –27.3; Figure 2).
Ten patients remained alive after a median follow-up of
24.0 months (range, 2.6 –45.5 months); 22 patients died
TABLE 1. Patient Demographics in 32 Patients with
Unresectable Non-small Cell Lung Cancer
Characteristics N (%), Unless Otherwise Stated
Age (yr)
50 6 (19)
50–59 11 (34)
60–69 9 (28)
70 6 (19)
Median (range) 57.5 (42–78)
Sex
Male 21 (66)
Female 11 (34)
Race
White 26 (81)
Black 6 (19)
Ethnicity
Hispanic 20 (63)
Non-Hispanic 12 (38)
ECOG performance status
0 16 (50)
1 16 (50)
Stage
IIIA 16 (50)
IIIB 16 (50)
Pathology
Squamous cell 10 (31)
Adenocarcinoma 11 (34)
Poorly differentiated 11 (34)
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Best Overall Response by RECIST in 32 Patients
Treated with Chemoradiotherapy with Carboplatin and
Irinotecan Followed by Consolidation Docetaxel
RECIST Category N (%) 95% Confidence Interval
Complete response* 4 (12.5)
Partial response 14 (43.8)
Complete and partial response 18 (56.3) 37.7–73.6%
Stable disease 4 (12.5)
Progressive disease 9 (28.1)
Not assesseda 1 (3.1)
* Division of Hematology/Oncology–Sylvester Comprehensive Cancer Center,
Univeristy of Miami, Leonard M. Miller School of Medicine, Miami, FL.
a Patient taken off from study for toxicity before response assessment.
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after a median follow-up of 7.0 months (range, 0.4 –30.0
months). Kaplan-Meier estimates of overall survival (Fig-
ure 2) were 54% (95% CI, 35–70%) at 1 year, 38% (95%
CI, 21–56%) at 2 years, and 19% (95% CI, 6–39%) at 3
years.
Toxicity
The most common hematologic toxicity was leukope-
nia, which was grade 3 in 14 patients and grade 4 in only 2
(Table 3). The most important nonhematologic toxicity was
radiation pneumonitis, which was grade 2 in five patients,
grade 3 in seven, and grade 4 in one. It was detected during
the follow-up period several weeks after radiation was com-
pleted and did not necessitate stopping chemoradiotherapy.
Radiation pneumonitis (grade2) occurred in 3 patients who
received chemoradiotherapy alone and in 10 who received
chemoradiotherapy followed by consolidation docetaxel. In
patients with radiation pneumonitis, CT scans of the chest
showed unilateral or bilateral interstitial or patchy infiltrates
inside the radiation fields. All patients and their radiation
ports were reviewed by our radiation oncologists to verify
these findings. The median V20 for patients with radiation
pneumonitis was 29%. All patients received symptomatic
therapy for radiation pneumonitis including steroids.
DISCUSSION
This phase II study was designed to evaluate the clin-
ical activity and feasibility of a new multimodality regimen
after the results of SWOG 95045 were released and before the
results of HOG LUN01-24/USO-0237 were available. In this
phase II study, chemoradiotherapy with carboplatin and iri-
notecan followed by consolidation docetaxel seemed to be
clinically active as evidenced by 18 (56.3%) objective re-
sponses among 32 patients. By comparison, the response rate
was 67% in SWOG 9504.5 Although the null response rate of
40% was not ruled out by our reported 95% CI (37.7–73.6%),
it was ruled out by our 90% CI (40.3–71.3%). The Kaplan-
Meier estimate of 2-year survival was 38% (95% CI, 21–
56%), and 10 patients remain alive with median follow-up of
24 months. Median survival, estimated at 14.8 months, com-
pared favorably with that reported in SWOG 90194 but may
be lower than that in recent phase III studies.6,7
We also sought a feasible alternative to commonly used
platinum-based doublets, which are associated with neutro-
penia, anemia, alopecia, nephropathy, neuropathy, and other
side effects. The rate of neutropenia was acceptable in our
study. The observed rate of radiation pneumonitis, including
FIGURE 1. Progression-free survival in 32 patients treated
with chemoradiotherapy with carboplatin and irinotecan fol-
lowed by consolidation docetaxel. Censored patients with-
out disease progression are shown with tick marks.
FIGURE 2. Overall survival in 32 patients treated with che-
moradiotherapy with carboplatin and irinotecan followed by
consolidation docetaxel. Censored patients who remained
alive are shown with tick marks.
TABLE 3. Most Common Adverse Events in 32 Patients
Treated with Chemoradiotherapy with Carboplatin and
Irinotecan Followed by Consolidation Docetaxel
Adverse Event
N (%)
Grade 1 or 2 Grade 3 or 4*
Hematologic events
Leukopenia 12 (38) 16** (50)
Neutropenia 13 (41) 8* (25)
Anemia 26 (81) 5* (16)
Thrombocytopenia 14 (44) 1 (3)
Nonhematologic events
Radiation pneumonitis 5 (16)a 8 (26)*a
Fatigue 16 (50) 1 (3)
Cough 14 (44) 1 (3)
Dysphagia 11 (34)
Vomiting 8 (25)
Radiation dermatitis 7 (22) 1 (3)
Alopecia 7 (22)
Heartburn 5 (16)
Dyspnea 3 (9)
Hemoptysis 2 (6)
Otherb 3 (9)
Each asterisk represents one patient with grade 4 toxicity.
a The percentage was based on 31 patients who underwent radiotherapy.
b One case each of neuropathic pain, cardiac ischemia, and thrombosis.
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eight patients with grade more than or equal to 3 (26%),
however, was unexpected compared with previous reports
(Table 4).5–7,10–14,23–27 Grade more than or equal to 3 pneu-
monitis occurred in no more than 15% of patients in early
Asian studies in which chemoradiotherapy with irinotecan
was administered alone10,11 or with carboplatin,12,13 except in
one study. Yamada et al.14 reported pneumonitis in 23% of
patients treated with irinotecan (30 to 60 mg/m2 weekly) and
carboplatin (20 mg/m2 for 5 days/wk). Radiation pneumonitis
occurred in 7 to 10% of patients in large cooperative group
studies of chemoradiotherapy with cisplatin and etoposide
followed by consolidation docetaxel.5–7
Of 32 patients entered, only 53% completed concurrent
chemoradiotherapy as opposed to 72.4% in the HOG LUN01-
24/USO-0237 and 88% in the SWOG95045 trial. We believe
that the main reason for this lower rate of completion was the
higher incidence of grade more than or equal to 3 radiation
pneumonitis in our trial at 26%. The incidence of radiation
pneumonitis was 7% in the SWOG9504 trial and 9.6% in the
HOG trial. The incidence of radiation pneumonitis did not
increase after the consolidation therapy in our study (data not
shown). The incidence of radiation pneumonitis was higher in
patients who were randomized to consolidation docetaxel in
the HOG study. Because our study was not randomized and
studied a smaller sample size, we can not conclude that
docetaxel contributed to an increase incidence of radiation
pneumonitis.
Radiation pneumonitis is an interstitial pulmonary in-
flammation. The radiographic hallmark is a diffuse infiltrate
corresponding to a previous treatment field. Two separate
mechanisms are involved in the pathogenesis of this acute
clinical phenomenon.28 The first, classic radiation pneumoni-
tis, involves direct toxicity to endothelial and epithelial cells
from the radiation, resulting in acute alveolitis. This process
leads to accumulation of inflammatory and immune cells
within the alveolar walls and spaces. The second mechanism,
sporadic radiation pneumonitis, results in an “out-of-field”
response. This is thought to be an immunologically mediated
process, resulting in bilateral lymphocytic alveolitis.28 Acute
radiation pneumonitis occurs within 1 to 6 months after
thoracic irradiation. Asymptomatic radiologic findings can be
detected in as many as 50% of treated patients, and radiation
pneumonitis develops in 5 to 35% of patients.29–31 The
incidence is often underreported, because symptoms can be
attributed to another cardiovascular or respiratory disorder.32
Symptoms can include low-grade fever, chest congestion,
shortness of breath, and dry cough. Severe reactions can
cause dyspnea, hemoptysis, pleuritic chest pain, acute respi-
ratory distress, and even death.
Potential risk factors for clinical radiation pneumonitis
include radiation dose expressed as mean lung dose,32–34 dosi-
metric parameters,33–34,36,37 and chemotherapy agents,32,38 but
the evidence is not consistent among studies partly because of
differences in variables considered in multivariate analyses,
criteria for grading pneumonitis, and method of delivering
radiotherapy and whether it was concurrent with chemother-
apy. For example, grading criteria and radiotherapy delivery
in SWOG 0023 were similar to ours, but they waited longer
after completing chemoradiotherapy before initiating do-
cetaxel (4–8 versus 3–4 weeks). Gaspar et al.37 recently
TABLE 4. Studies of Patients with Non-small Cell Lung Cancer Treated with Chemoradiotherapy
Reference
Response Rate,
n/N (%)
Median Survival,
mo
Pneumonitis Grade
>3, n/N (%)
Irinotecan alone
Choy et al.10 7/12 (58) NR NR
Takeda et al.11 20/26 (76.9) 15.7 74/26 (15)
Irinotecan and carboplatin
Chakravarthy et al.12 11/18 (61) NR NR
Uejima et al.13 21/30 (72) Not reached Grade 2, 3/29 (10)
Yamada et al.14 18/30 (60) 14.9 7/30 (23)
Irinotecan and cisplatin
Fukuda et al.23 40/48 (83) 21 5/48 (10)
Langer et al.24 11/15 (73) 28 1/15 (7)
Oka et al.25 16/23 (70) NR 0/23 (0)
Takiguchi et al.26 6/12 (50) 10.1 NR
Induction irinotecan 3 chemoradiotherapy with cisplatin
Kawahara et al.27 NR (64.7) 16.5 6/49 (13)
Induction cisplatin and etoposide 3 consolidation docetaxel
SWOG 95045 56/83 (67) 26 6/83 (7); 2 deaths
SWOG 00236a NR 23 vs 35 38/543 (7); 6 deaths
HOG LUN 01–24/USO-0237b NR 21 vs 23 NR (10 vs 1); 1 death
Irinotecan and carboplatin 3 consolidation docetaxel
This study 18/32 (56.3) 14.8 8/31 (26)
a After induction, patients received consolidation docetaxel with or without gefitinib; survival results reflect gefitinib versus no gefitinib.
b After induction, patients received consolidation docetaxel or no consolidation; survival and pneumonitis results reflect docetaxel versus no docetaxel.
NR, not reported; SWOG, Southwest Oncology Group.
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reported that the incidence of grade more than or equal to 3
radiation pneumonitis was highly correlated with V20 more
than 35% (p  0.01) in SWOG 0023 and was an independent
factor in Cox regression analysis adjusted for other variables.
This does not totally explain our findings as V20 was 29% in
our patients with radiation pneumonitis. The chemotherapy
used in combination with radiotherapy was paclitaxel or
etoposide in most previously published clinical studies,
whereas we chose irinotecan as a radiation enhancer. Yamada
et al.38 reported a significantly higher incidence of grade more
than or equal to 2 radiation pneumonitis among patients who
received radiotherapy concurrently with irinotecan than
among those who did not (56 versus 14%). Therefore, the
increased incidence of radiation pneumonitis in our study is
probably also because of the use of a novel chemotherapeutic
agent (irinotecan).
Patients with forced expired volume in 1 second less
than 2 L are at a higher risk of developing radiation pneu-
monitis.39 In our study, baseline pulmonary function tests
were strongly encouraged but not mandatory, because the
patients had an excellent overall performance status, absence
of chronic obstructive pulmonary disease, and other clinical
parameters that could negatively impact their pulmonary
reserve. The patients who were able to receive docetaxel were
younger and had better performance status at diagnosis,
therefore, this may justify why these patient subgroup had a
lower incidence of high-grade radiation pneumonitis. The
main risk factors identified in our study for the development
of radiation pneumonitis were age, performance status, and
stage of the disease. As we previously mentioned, the irino-
tecan was likely the cause for the higher incidence of radia-
tion pneumonitis in our study based on the V20 results.
Two randomized trials have been recently reported
exploiting the concept of chemoradiotherapy followed by
consolidation chemotherapy.7,40 One used weekly paclitaxel
and cisplatin followed by monthly paclitaxel and cisplatin for
three additional cycles.40 HOG LUN01-24/USO-023 used
weekly cisplatin and etoposide followed by 3 cycles of
docetaxel.7 Both trials failed to demonstrate improvement in
overall survival with consolidation strategies.
In conclusion, the results of this phase II study sug-
gested that concurrent chemoradiotherapy with carboplatin
and irinotecan followed by consolidation with docetaxel is
clinically active based on median survival in patients with
unresectable stage III NSCLC. The 42% incidence of grade
more than or equal to 2 radiation pneumonitis was unexpected
and warrants investigation to determine the mechanism and
preventive strategies before further clinical evaluation of this
regimen. Furthermore, consolidation chemotherapy with do-
cetaxel failed to demonstrate improvement in overall survival
in HOG LUN 01-24/USO 02-0337; however, the median
survival with consolidation docetaxel in these studies is
appealing and might represent a better approach to the con-
cept of consolidation—possibly with less toxic chemotherapy
regimens during radiation. Further clinical studies are needed
to define the optimal chemotherapy regimen and the use of
novel radiotherapy techniques, which may be less toxic and
can improve overall survival in patients with unresectable
stage III NSCLC.
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